Accelerated Pharma (Accelerated Pharma) Days Payable : 0.00 (As of Mar. 2017)

View and export this data going back to 2016. Start your Free Trial

What is Accelerated Pharma Days Payable?

Accelerated Pharma's average Accounts Payable for the three months ended in Mar. 2017 was $0.90 Mil. Accelerated Pharma's Cost of Goods Sold for the three months ended in Mar. 2017 was $0.00 Mil.

The historical rank and industry rank for Accelerated Pharma's Days Payable or its related term are showing as below:

ACCP's Days Payable is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 87.51
* Ranked among companies with meaningful Days Payable only.

Accelerated Pharma's Days Payable stayed the same from Mar. 2016 (0.00) to Mar. 2017 (0.00). stayed the same

Accelerated Pharma Days Payable Historical Data

The historical data trend for Accelerated Pharma's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accelerated Pharma Days Payable Chart

Accelerated Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Days Payable

Accelerated Pharma Quarterly Data
	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17
Days Payable	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of Accelerated Pharma's Days Payable

For the Drug Manufacturers - Specialty & Generic subindustry, Accelerated Pharma's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Accelerated Pharma's Days Payable Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Accelerated Pharma's Days Payable distribution charts can be found below:

* The bar in red indicates where Accelerated Pharma's Days Payable falls into.

Accelerated Pharma Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Accelerated Pharma's Days Payable for the fiscal year that ended in Dec. 2016 is calculated as

	Days Payable (A: Dec. 2016 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2015 )	+	Accounts Payable (A: Dec. 2016 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2016 )	*	Days in Period
=	( (0.597	+	0.879)	/	2 )	/	0	*	365
=	0.738					/	0	*	365
=	N/A

Accelerated Pharma's Days Payable for the quarter that ended in Mar. 2017 is calculated as:

	Days Payable (Q: Mar. 2017 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Dec. 2016 )	+	Accounts Payable (Q: Mar. 2017 ))	/	count )	/	Cost of Goods Sold (Q: Mar. 2017 )	*	Days in Period
=	( (0.879	+	0.913)	/	2 )	/	0	*	365 / 4
=	0.896					/	0	*	365 / 4
=	N/A

Accelerated Pharma Days Payable Related Terms

Thank you for viewing the detailed overview of Accelerated Pharma's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Accelerated Pharma (Accelerated Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Accelerated Pharma Inc (NAS:ACCP) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Accelerated Pharma Inc, is a Delaware corporation organized on May 12, 2014. It is a biopharmaceutical company focused on utilizing its genomic technology to enhance the development and commercialization of pharmaceutical products. Its lead product candidate is Picoplatin, a new generation platinum-based cancer therapy that has the potential for use in different formulations, as a single agent or in combination with other anti-cancer agents, to treat multiple cancer indications.

Accelerated Pharma (Accelerated Pharma) Headlines

No Headlines